If you’ve been losing weight with semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), you may have seen incredible results—40, 50, or more pounds gone. But with the shortage resolved as of May 2025, your provider may switch you to liraglutide (Saxenda) or dulaglutide (Trulicity). Here’s the truth: weight loss after the GLP-1 shortage may slow down without the right support. STAAR LABS’ SLM+ is the key to keeping your progress on track. Learn why SLM+ is a must-have with liraglutide to continue seeing noticeable results.

What to Expect After Switching to Liraglutide or Dulaglutide

Semaglutide and tirzepatide have been amazing for weight loss:

Semaglutide: Many patients lose 40–50 lbs, or 20% of their body weight.
Tirzepatide: Some lose 50+ lbs, or 25% of their body weight.

But liraglutide and dulaglutide alone don’t compare:

Liraglutide: You might lose only 10–20 lbs, or 5–10% of your body weight.
Dulaglutide: Weight loss is often just 5–15 lbs, or 3–6% of your body weight.

Without extra support, your weight loss may stall, and you might feel nausea or stomach discomfort in the first 4–6 weeks as your body adjusts. Don’t give up—SLM+ can help you keep losing weight.

Why SLM+ Is Essential for Weight Loss After the GLP-1 Shortage

SLM+ works with liraglutide and dulaglutide to boost your weight loss results:

Enhances GLP-1 Levels: Increases GLP-1 by up to 25%, helping you feel full longer and eat less.
Speeds Up Fat Burning: Revs up your metabolism for faster results.
Reduces Nausea: Makes your therapy easier to stick with by minimizing stomach issues.

Patients using SLM+ with STAAR LABS’ GPS Protocols have lost up to 46 lbs—results that match what you saw with semaglutide or tirzepatide. Without SLM+, you might struggle to lose even half that amount.

Take Control of Your Weight Loss Today

Don’t let the switch to liraglutide or dulaglutide slow your progress. Ask your provider or pharmacy about adding SLM+ to your routine to keep losing weight and feeling your best. Visit www.staarlabs.com to learn more about SLM+ and the GPS Protocols, and take the first step toward unstoppable results.

___________________________________________________________________

Medical Disclaimer: This blog is for informational purposes only and is not intended as medical advice. GLP-1 medications such as tirzepatide, semaglutide, liraglutide and dulaglutide, and amylin analogues such as pramlintide, are prescription medications; consult your provider before starting. Always consult your healthcare provider before making any changes to your medications, supplements, or health regimen. Individual results may vary.

Supplement Disclaimer: Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Research & Innovation Disclosure: STAAR LABS conducts protocol development in collaboration with licensed providers and pharmacies. Our research focuses on combining nutraceutical and pharmaceutical interventions to enhance metabolic outcomes. Weight loss projections involving SLM+ are based on early observational feedback and theoretical mechanisms, not yet published in peer-reviewed clinical trials.

For full disclaimers, visit www.staarlabs.com.